BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue
+33.8%
EPS
+143.7%
Free cash flow
+33.6%
Total debt
+491.3%

Quarter to September 2026, against a year earlier

406.26 19.01 +4.91%
Market cap
$40.4B
P/E
68.9×
Fwd P/E
48.8×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
7 4 3 3 6 4 2 3 4 4
P/E ratio
116.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
6.20 5.10 7.51 16.51 21.37 69.83 23.25 39.23 17.64 167.75
Altman Z-Score
5.25 3.16 3.29 5.26 5.87 6.50 6.67 8.74 7.11 9.93
Altman Z″-Score (non-manufacturers)
1.78 (2.06) (1.53) 0.65 4.23 2.84 (2.83) 5.09 5.11 8.64
P/FCF ratio
35.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
79.39 258.75 (83.36) (73.46) (49.50) (64.90) (37.26) (40.11) 44.93 (36.88)
Beneish M-Score
(2.73) (2.15) (1.51) (3.24) 0.94 (3.12) (2.11) (2.55) — —
P/B ratio
7.60 5.84 5.22 5.33 4.10 5.57 10.17 4.43 6.16 2.73
EV/Sales
5.59 4.54 6.44 13.68 16.30 56.50 21.54 31.17 14.82 106.69
EV/EBITDA
50.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF
32.41 (27.14) (8.92) (10.38) (11.94) (12.45) (10.97) (9.40) (76.98) (5.43)
Current Ratio
3.41 1.80 2.32 3.55 4.76 4.61 3.78 7.89 6.09 10.68
Net Debt/EBITDA
(6.09) 6.21 2.66 2.32 4.29 2.53 0.78 2.30 7.18 3.05
Debt/Equity
0.22 0.05 0.06 0.12 0.11 0.14 0.26 0.11 0.24 0.05
ROE
7.46% (18.77%) (22.26%) (38.11%) (29.15%) (65.88%) (69.45%) (55.28%) (17.95%) (94.94%)
ROA
4.07% (11.00%) (14.47%) (26.87%) (20.63%) (44.28%) (49.13%) (40.88%) (12.82%) (45.63%)
ROIC
36.03% (40.76%) (134.04%) (289.43%) (541.89%) 0.00% (243.08%) (282.66%) (538.37%) (3,627.29%)
Return on Tangible Assets
4.75% (19.22%) (23.72%) (43.71%) (22.08%) (37.63%) (85.87%) (36.33%) (11.27%) (32.63%)
Average Days of Receivables
59.10 64.78 53.15 44.64 149.91 71.38 60.42 75.60 45.06 0.00
Earnings Yield
0.86% (3.32%) (4.77%) (8.60%) (5.58%) (7.36%) (9.50%) (8.56%) (2.17%) (12.33%)
Free Cash Flow Yield
2.78% (3.28%) (9.60%) (7.98%) (6.39%) (6.50%) (8.45%) (8.45%) (1.09%) (11.72%)
Free Cash Flow per Share
8.45 (6.06) (16.66) (17.67) (17.30) (16.78) (13.99) (11.85) (1.10) (3.64)
Book value per Share
39.99 31.65 33.89 42.50 66.09 46.35 16.29 31.63 16.38 11.37
Free Cash Flow
921.74 (637.97) (1,738.71) (1,822.05) (1,605.07) (1,400.97) (839.88) (656.85) (45.98) (113.01)
EV/EBIT
66.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026